Intracellular expression of antibodies provides a novel approach for the manipulation of biochemical processes in intact cells. We have used this approach to test two alternative strategies for the...
In the adult brain, multipotent progenitor cells have been identified in three areas: the ventricular-subventricular zone (VZ-SVZ), adjacent to the striatal wall of the lateral ventricles, the subgranular zone (SGZ), located at the dentate gyrus of the hippocampus and the subcallosal zone (SCZ), located between the corpus callosum and the CA1 and CA2 regions of the hippocampus. The neural progenitor cells of these regions express the epidermal growth factor receptor (EGFR, ErbB-1 or HER1). EGF, the most important ligand for the EGFR, is a potent mitogenic agent that stimulates proliferation, survival, migration and differentiation into the oligodendrocyte lineage. Other ErbB receptors also activate several intracellular pathways for oligodendrocyte specification, migration and survival. However the specific downstream pathways related to oligodendrogenesis and the hierarchic interaction among intracellular signaling cascades is not well-known. We summarize the current data regarding the role of
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
184 ERBB4 is a receptor tyrosine kinase belonging to the ERBB receptor family. Similar to the other ERBB members, ERBB4 binds ligand, dimerizes, and autophosphorylates its carboxyterminal tyrosines allowing recruitment of adapter proteins and subsequent activation of MAPK, STAT, PLC-gamma and PI3K signaling pathways. Unique to ERBB4, ligand binding leads to a two-step proteolysis of ERBB4 involving TACE and gamma-secretase to release the cytoplasmic domain, termed ERBB4 s80. ERBB4 s80 is an active tyrosine kinase that localizes to both the cytosol and nucleus. ERBB4 is found in the nucleus of the lactating mammary gland and in some breast cancer tissues. Little is known, however, about how nuclear ERBB4 s80 regulates mammary gland differentiation and cancer progression. To understand how ERBB4 s80 alters differentiation and cancer progression, we investigated whether ERBB4 could regulate MTG16 function. MTG16 (also known as ETO2 or CBFA2T3) is a transcriptional corepressor that regulates ...
Dysregulation of the epidermal growth factor receptor family (EGFR, HER2, HER3, HER4) by mutation and/or overexpression plays an important role in tumorigenesis, and targeted agents directed against two members of the HER/ErbB family, epidermal growth factor receptor (EGFR/HER1), and HER2/ErbB2, are used in the treatment of cancer. Extensive crosstalk seen among these receptors implies that blocking signaling of more than one receptor may be more effective in inhibiting tumor growth and circumventing resistance mechanisms than targeting individual receptors. In particular, HER3 is considered a key mediator of resistance to many targeted agents. We generated a "two-in-one" antibody, MEHD7945A, that binds to EGFR and HER3 with high affinity, inhibits receptor function and is more broadly efficacious in various tumor types when compared to monospecific anti-EGFR or anti-HER3 antibodies. Given the ability of HER3 to potently activate the PI3K survival pathway, we investigated if antagonizing ...
The ErbB protein family or epidermal growth factor receptor (EGFR) family is a family of four structurally related receptor tyrosine kinases. Insufficient ErbB signaling in humans is associated with the development of neurodegenerative diseases, such as multiple sclerosis and Alzheimers Disease. In mice loss of signaling by any member of the ErbB family results in embryonic lethality with defects in organs including the lungs, skin, heart and brain. Excessive ErbB signaling is associated with the development of a wide variety of types of solid tumor. ErbB-1 and ErbB-2 are found in many human cancers and their excessive signaling may be critical factors in the development and malignancy of these tumors. The ErbB protein family consists of 4 members ...
M.BELIMEZI, B. FILIPPI, K. VOURVOUHAKI, A. MAMALAKI). The oncoprotein HER2/neu (c-erbB-2) is a member of the erbB receptor family with tyrosine kinase activity. It is the principal component of the heterodimers that are formed among members of the erbB family (EGFR, erbB-3, erbB-4) in the presence of growth factors, which result in the activation of those signaling pathways that lead to cell proliferation and differentiation. Any alteration in the tightly regulated signaling cascade of HER-2/neu cause severe abnormalities and carcinogenesis. HER2/neu is overexpressed in approximately 30% of human breast and ovarian cancer, and has been associated with aggressiveness and poor prognosis. In addition, HER2/neu has been shown to be overexpressed, in a large number of other human malignancies including ovarian, colon, lung, prostate and cervical cancers. HER2/neu overexpression in neoplasmatic cells activates the immune system, as it is detected from the increased title of antibodies against HER2/neu ...
|p|Description:|br /|IC50: AZD8931 showed equipotent, reversible inhibition of EGFR (IC50, 4 nmol/L), erbB2 (IC50, 3 nmol/L), and erbB3 (IC50, 4 nmol/L) phosphorylation in cells|br /|The erbB receptor family is composed of four related receptor tyrosine k
ウサギ・ポリクローナル抗体 ab15140 交差種: Hu 適用: WB,IHC-P…ErbB 4抗体一覧…画像、プロトコール、文献などWeb上の情報が満載のアブカムの Antibody 製品。国内在庫と品質保証制度も充実。
ErbB 4兔单克隆抗体[E200](ab32375)可与小鼠, 大鼠, 人样本反应并经WB, IP, IHC, ICC, Flow Cyt实验严格验证,被11篇文献引用并得到1个独立的用户反馈。
High-quality ErbB3 proteins from ACROBiosystems. Various species and tags of ErbB3 proteins. Minimal Batch-to-Batch Variation. Bulks in stock.
Plasmid MSCV-human Erbb2-IRES-GFP from Dr. Martine Roussels lab contains the insert Erbb2 and is published in Cell Rep. 2017 Mar 21;18(12):2907-2917. doi: 10.1016/j.celrep.2017.02.073. This plasmid is available through Addgene.
高い抗原親和性、特異性と安定した品質を兼ね備えたアブカムのウサギ・モノクローナル抗体 RabMAb® ab68478 交差種: Hu 適用: WB,IP,IHC-P
Both standard and v3 isoforms of CD44 were overexpressed in TamR cells at both gene and protein levels (mean fold increase in CD44s protein (TamR versus MCF7): 4.26 ± 1.2, P , 0.05). Moreover, CD44s and v3 colocalised with Her2 and Her3 receptors at the cell surface and were also detectable in Her2/Her3 cellular immunoprecipitates. Treatment of TamR cells with heregulin resulted in phosphorylation of erbB receptors together with a number of downstream signalling intermediates, including Akt, Src and FAK, and resulted in enhanced cellular migration. Significantly, heregulin-induced intracellular signalling was dramatically reduced in cells in which the expression of CD44 was suppressed (via siRNA), with a corresponding loss of heregulin-induced migratory behaviour (mean fold change in cell migration versus untreated control: 6.7 ± 1.1, P , 0.05 (heregulin beta 1); 1.8 ± 0.9 (CD44 siRNA); 1.47 ± 0.6, P , 0.05 (heregulin beta 1 + CD44 siRNA)). ...
The neuregulins are a subset of the ligands for the epidermal growth factor receptor family of receptors. They can bind to these receptors and evoke a range of cellular responses. Some of the neuregulins have however been found in the cell nucleus associated with nucleoli and intrachromatin granules. This brief review summarises the data for nuclear expression obtained from observations on normal and malignant tissues and the various laboratory experiments conducted to explore the system. Finally, we discuss the possible functions that could result from intra-nuclear expression of these molecules.. ...
Does anyone out there know if there is a commercial supplier of an antibody raised against the growth factor ligand heregulin ? Any help or advice would be greatly appreciated.... Jonathan Harris Hammersmith Hospital London UK ...
inproceedings{444095, author = {Stove, Christophe and Boterberg, Tom and Derycke, Lara and VANDEKERKHOVE, D and Mareel, Marcus and Bracke, Marc}, booktitle = {Acta Clinica Belgica}, issn = {0001-5512}, pages = {205--205}, title = {An anti-invasive factor in the conditioned medium of a melanoma cell line: signaling via the ErbB receptors?}, volume = {58}, year = {2001 ...
Biological Process: cranial nerve development; endocardial cushion development; ERBB2 signaling pathway; heart development; MAPK cascade; negative regulation of cell adhesion; negative regulation of ERBB signaling pathway; negative regulation of neuron apoptosis; negative regulation of secretion; negative regulation of signal transduction; neuron apoptosis; peptidyl-tyrosine phosphorylation; peripheral nervous system development; phosphatidylinositol phosphorylation; phosphoinositide 3-kinase cascade; positive regulation of cardiac muscle tissue development; positive regulation of gene expression; positive regulation of phosphoinositide 3-kinase cascade; positive regulation of protein kinase B signaling; regulation of cell motility; regulation of cell proliferation; Schwann cell differentiation; signal transduction; transmembrane receptor protein tyrosine kinase signaling pathway; wound healing ...
购买ErbB 4兔单克隆抗体[EP2272AY](ab76132),ErbB 4抗体经WB验证,可与人,小鼠,大鼠样本反应。产品出库一年都在质保范围内。中国现货速达。
The ErbB family of receptor tyrosine kinases includes EGFR, ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4. Abundant evidence supports the causal role of HER2 overexpres...
Applications Treatment of cancers that possess the ErbB receptors (e.g. colorectal, liver, bladder, and head and neck tumors)Advantages
The selective erbB2 antagonist AG825 dampens the NRG1α-induced MRVA.Administration of AG825 in DMSO vehicle (n = 5) caused a robust, dose-dependent decreas
Clone REA508 recognizes the human ErbB-3 antigen, a single-pass type I membrane protein, which is also known as tyrosine kinase-type cell surface receptor HER3. ErbB-3 is a receptor tyrosine kinase and a member of the epidermal growth factor receptor family (EGFR). It is unique among the ErbB family members in that it is has been shown to have weak or no tyrosine kinase activity. After dimerization with other members of the EGFR family several signal transduction cascades can be activated, including phosphoinosite 3-kinase (PI3-K)/Akt and extracellular signal-regulated kinase (ERK1/2). ErbB-3 is widely expressed in normal tissues including cells of the gastrointestinal, reproductive, respiratory and urinary tracts, as well as the skin, endocrine, and nervous system. It is expressed at elevated levels in a range of human malignancies. Additional information: Clone REA508 displays negligible binding to Fc receptors. - Principat dAndorra
Looking for online definition of ErbB-3 in the Medical Dictionary? ErbB-3 explanation free. What is ErbB-3? Meaning of ErbB-3 medical term. What does ErbB-3 mean?
Creative Biolabs provides Anti-ErbB2 (C6.5G98A) h(CD28-CD3ζ) CAR, pCDCAR1 product for Biopharmaceutical research,preclinical and clinical trials.
(2013) Schokoroy et al. PLoS ONE. Background:The ErbB receptors, Ras proteins and nucleolin are major contributors to malignant transformation. The pleiotropic protein nucleolin can bind to both Ras protein and ErbB receptors. Previously, we have demonstrated a crosstalk between Ras, nucleolin an...
The small GTPase Rac1 has been widely implicated in mammary tumorigenesis and metastasis. Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac-GEF P-Rex1. As the Jak2/Stat3 pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands. Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells. However, Rac1 activation was not affected by Jak2 or Stat3 RNAi, suggesting that the effect of cucurbitacin I occurs through a Jak2-independent mechanism. Cucurbitacin I also failed to affect the activation of P-Rex1 by heregulin. Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector ROCK in breast cancer cells and induces the formation of stress fibers. ...
... with 101 pages available at USD 3500 for single User PDF at ReportsWeb research database.
|p|erbB-2|strong| |/strong|is a transmembrane, tyrosine kinase (TK) receptor whose overexpression is associated with adverse prognosis in breast cancer|sup|1|/sup|.|/p| |p|The human epidermal growth factor receptor (erbB-2) is a transmembrane receptor th
At the time of initial biopsy, 20 (42.6%) of 47 samples demonstrated high levels of HER2/erbB-2 expression. Higher frequencies of expression were observed in samples from patients with metastatic disease at presentation and at the time of relapse. Expression of HER2/erbB-2 correlated with a significantly worse histologic response (P =.03). In patients presenting with nonmetastatic disease, expression of HER2/erbB-2 at the time of initial biopsy was associated with a significantly decreased event-free survival (47% v 79% at 5 years, P =.05). p53 and p-glycoprotein expression did not correlate with histologic response or patient event-free survival. Conclusion: ...
The importance of ErbB receptors in development is proven from the analysis of genetically modified mice. Indeed, null mutations in individual ErbB loci are lethal. More specifically, depending upon the genetic background of the host, loss of ErbB1 leads to embryonic or perinatal lethality with mice showing abnormalities in multiple organs including the brain, skin, lung and gastrointestinal tract (Miettinen et al., 1995; Sibilia and Wagner, 1995; Threadgill et al., 1995; Sibilia et al., 1998). ErbB2 null mice die at midgestation (E10.5) due to trabeculae malformation in the heart (Lee et al., 1995), a phenotype that is shared by ErbB4 knockout mice (Gassmann et al., 1995). In addition, through genetic rescue of heart development via myocardial expression of an ErbB2 transgene, a further role for ErbB2 in peripheral nervous system development has been demonstrated (Morris et al., 1999). In the case of ErbB3, most knockout mice die by E13.5, displaying normal heart trabeculation but defective ...
The progression of a primary mammary epithelial cell to the malignant phenotype is thought to involve multiple genetic events including the activation of domina...
A series of chimeric receptors was generated between the epidermal growth factor (EGF) receptor, ErbB-1, and its homologue, ErbB-4, to investigate the roles of the extracellular domains (I-IV) in the ligand specificities. As compared with ErbB-1 and the chimeras with both domains I and III of ErbB-1, the chimeras with only one of these domains exhibited reduced binding of 125I-labeled EGF. Particularly, the contribution of domain III was appreciably larger than that of domain I of ErbB-1 in 125I-labeled EGF binding. ...
Abcam provides specific protocols for Anti-ErbB 2 antibody [ICR55] (ab11711) : Immunoprecipitation protocols, Immunohistochemistry protocols, Western blot…
Acts as an adapter for the receptor ERBB2, in epithelia. By binding the unphosphorylated ERBB2 Tyr-1248 receptor, it may contribute to stabilize this unphosphorylated state (By similarity). Inhibits NOD2-dependent NF-kappa-B signaling and proinflammatory cytokine secretion (PubMed:16203728).
Semantic Scholar extracted view of A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. by Kermit L. Carraway et al.
Complete information for ERBB2 gene (Protein Coding), Erb-B2 Receptor Tyrosine Kinase 2, including: function, proteins, disorders, pathways, orthologs, and expression. GeneCards - The Human Gene Compendium
public: HRG_RESULT Initialize (IX_DEV_ID device_id, const IX_INFO *p_info); HRG_RESULT StartTimer( ); HRG_RESULT StopTimer( ); HRG_RESULT GetElapsedSeconds(double *p_seconds); HRG_RESULT GetTreadmillInfo(IX_DEV_INFO *p_info); HRG_RESULT GeTreadmillStatus(IX_DEV_STATUS *p_status); HRG_RESULT GetSpeed(doulbe *p_speed); HRG_RESULT GetSpeedRange(IX_SCALAR_RANGE *p_range); HRG_RESULT GetSpeedUnits(IX_ITEM_UNITS *p_units); HRG_RESULT SetSpeed(double speed); HRG_RESULT GetIncline(double *p_incline); HRG_RESULT GetInclineRange((IX_SCALAR_RANGE *p_range); HRG_RESULT GetInclineUnits(IX_ITEM_UNITS *p_units); HRG_RESULT SetIncline(double incline); HRG_RESULT GetHeartRate(double *p_heart_rate); HRG_RESULT GetHeartRateRange(IX_SCALAR_RANGE *p_range); HRG_RESULT GetHeartRateUnits(IX_ITEM_UNITS *p_units); HRG_RESULT GetPower(double *p_power); HRG_RESULT GetPowerRange(IX_SCALAR_RANGE *p_range); HRG_RESULT GetPowerUnits(IX_ITEM_UNITS *p_units); HRG_RESULT GetPace(double *p_pace); HRG_RESULT ...
Register to receive updates on PERJETA® (pertuzumab) from Genentech. See Full Safety including Boxed Warnings for more information.
ErbB (epidermal growth factor receptor) family is a drug target for treating several types of cancers, including lung and breast cancers. ErbB family of receptor tyrosine kinases consists of EGFR, HER2, ErbB3, and ErbB4. Overexpression of EGFR is observed in 62% of NSCLC tumors(nonsmall cell lung cancer) and overexpression of EGFR and HER2 are important prognostic markers for breast cancer. Members of the ErbB family share a similar overall structural architecture comprising: (i) extracellular ligand binding domain, (ii) transmembrane domain, (iii) intracellular juxtamembrane domain, (iv) intracellular tyrosine kinase domain, and (v) C-terminal regulatory region where phosphorylation occurs. We are interested in targeting the tyrosine kinase domain(TKD). Approved small molecules of the TKD domain include erlotinib Tarceva, OSI Pharmaceuticals), gefitinib (Iressa, AstraZeneca), and lapatinib (Tykerb, Glaxo-SmithKline). A fourth compound called AEE788 (Novartis) is in development. Among them, ...
The family of Neuregulins (NRG), growth factors like epidermal growth factor, is known to induce growth and differentiation of epithelial, glial, neuronal, and skeletal muscle cells. This family comprises four members, being NRG1 the most largely studied, particularly at the cardiovascular level. The biological effects of NRG1 in the adult heart are mediated by the tyrosine kinase receptors ErbB. In the adult heart, NRG1 is expressed by cells of the endocardial endothelium and the cardiac microvascular endothelium, and the receptors ErbB2/ErbB4 are expressed by ventricular cardiomyocytes and are located in T-tubule system and intercalated disks in close proximity to the system components of excitation-contraction coupling. The importance of the NRG/ErbB signaling axis at the cardiovascular level became evident after discovering that patients treated with trastuzumab (inhibitory antibody against ErbB2, used in the treatment of breast cancer) can develop ventricular dysfunction and have higher ...
Fusion protein amino acids 1-75 (membrane-associated N-terminus) of human Neuregulin-1 (also known as NRG1, Neu differentiation factor, NDF, Heregulin, HRG, HGL, Breast cancer cell differentiation factor p45, Acetylcholine receptor-inducing activity, ARIA, Glial growth factor, GGF, Sensory and motor-neuron-derived factor or SMDF, accession number Q96IB3); Mouse: 85% identity (64/75 amino acids identical); Rat: 82% identity (63/76 amino acids identical). ...
The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or ...
Research by Dr. Paul Clark, a scientist in Kuos lab and the studys lead author, shows why. When cetuximab treatment switches off EGFR activity and should inhibit cancer-cell growth, cancer stem cells compensate by turning on two other EGFR family receptors (ERBB2 and ERBB3) and continue to grow. One of these receptors, ERBB2, is implicated in certain types of chemotherapy-resistant breast cancer. Fortunately, another novel drug already approved by the FDA, lapatinib, inhibits ERBB2 activity and signaling by multiple EGFR members.. This study shows that cancer stem-cell growth was markedly inhibited by lapatinib treatment, which results in combined knockout of multiple EGFR family members.. "This is good news, because these drugs target an important mechanism for the (GBM) cancer cells to grow so quickly and evade current therapies, and these molecularly targeted drugs are also well-tolerated by patients and have minimal side effects," Dr. Clark said.. ...
ErbB1 HER1 EGFR ErbB2 HER2 Neu ErbB3 HER3 ErbB4 HER4 I II III IV I II III IV I II III IV I II III IV Extracellular Cytoplasmic Transmembrane Kinase Domain N C N N C C C-terminal tail Zahnow, C.A., Expert Rev Mol Med The EGFR family of Receptor Tyrosine Kinases { EGFRHer2/neuHer3Her4 Kinase Domain Inactive
Glioblastoma (GBM) is often resistant to conventional and targeted therapeutics. ERBB4 is expressed throughout normal brain and is an oncogene in several pediatric brain cancers; therefore, we investigated ERBB4 as a prognostic marker and therapeutic target in GBM. Using RT-qPCR, we quantified mRNA encoding total ERBB4 and known ERBB4 variants in GBM and non-neoplastic normal brain (NNB) samples. Using immunohistochemistry, we characterized the localization of total and phosphorylated ERBB4 (p-ERBB4) and EGFR protein in archived GBM samples and assessed their association with patient survival. Furthermore, we evaluated the effect of ERBB4 phosphorylation on angiogenesis and tumorigenicity in GBM xenograft models. Total ERBB4 mRNA was significantly lower in GBM than NNB samples, with the JM-a and CYT-2 variants predominating. ERBB4 protein was ubiquitously expressed in GBM but was not associated with patient survival. However, high p-ERBB4 in 11% of archived GBM samples, independent of p-EGFR, was
Blog on anti-Erbb2 antibody product: The Erbb2 erbb2 (Catalog #MBS9209362) is an Antibody produced from Rabbit and is intended for research pu...
Oncogene ERBB4 (HER4) is a member of the type I receptor protein tyrosine subfamily that includes EGFR, ERBB2, and ERBB3. ERBB4 binds and is activated by neuregulins and other factors and induces a variety of cellular responses including mitogenesis and differentiation.
Her2 / ErbB2 antibody [RM228] (erb-b2 receptor tyrosine kinase 2) for IHC, WB. Anti-Her2 / ErbB2 mAb (GTX33616) is tested in Human samples. 100% Ab-Assurance.
Active Motif offers research kits, assays and biocomputing systems that help researchers study the function, regulation and interactions between genes, proteins and metabolic pathways.